Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Systemic Sclerosis Patients Have Activating Antibodies Worse Prognosis


  • Please log in to reply
No replies to this topic

#1 Guest_Jude the Grouch_*

Guest_Jude the Grouch_*
  • Guests

Posted 17 September 2007 - 10:34 AM

Systemic Sclerosis Patients Have Activating Antibodies Targeting Both Endothelin Receptor Type A And Angiotensin Ii Type 1 Receptor Predicting Worse Prognosis. Anti-AT1R and anti-ETAR antibodies are a biomarker for severe disease and worse prognosis and could explain pathogenic features found in systemic sclerosis. The detection of these antibodies could identify SSc patients that might benefit from a receptor blockade or from a specific modulation of the antibody-receptor interaction. G. Riemekasten OP0162 EULAR 2007. (Also see: Causes of Scleroderma: Endothelin, Antibodies,and Prognosis)